TCA
BIO icon

Transcend Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Transcend Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Sell
1,519
-2
-0.1% -$567 0.03% 494
2026
Q1 		$424K Buy
1,521
+647
+74% +$186K 0.03% 428
2025
Q4 		$265K Buy
+874
New +$273K 0.02% 561

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Transcend Capital Advisors's BIO Position: Q2 2026 in Review

Transcend Capital Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 0.13% in Q2 2026, selling an estimated $567 and leaving 1,519 shares worth $446K. The position accounts for 0.03% of the portfolio, ranked #494.

Transcend Capital Advisors first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Transcend Capital Advisors held 1,519 shares of Bio-Rad Laboratories Class A worth $446K as of Q2 2026.
  • Transcend Capital Advisors sold 2 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $567.
  • Bio-Rad Laboratories Class A made up 0.03% of Transcend Capital Advisors's portfolio in Q2 2026, its #494 holding.
  • Transcend Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.